Clinical Trials Sponsored by BioCryst Pharmaceuticals

Total 19572 results

BioCryst Pharmaceuticals

Recruiting

Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

South Africa, Malaysia
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy (REDEEM-2)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Malaysia, South Africa, Korea, Republic of
BioCryst Pharmaceuticals

Active, not recruiting

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (APeX-A)

Hereditary Angioedema | HAE

France, North Macedonia, Poland, Korea, Republic of, Slovakia, South Africa, Czechia
BioCryst Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan (APeX-J)

Hereditary Angioedema, HAE

Japan
BioCryst Pharmaceuticals

Completed

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (APeX-1)

Hereditary Angioedema (HAE)

Canada, United Kingdom, Germany, Spain, Australia, Hungary, Italy, Austria, North Macedonia, Denmark, Switzerland
BioCryst Pharmaceuticals

Completed

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

Influenza

United States
BioCryst Pharmaceuticals

Completed

A Relative Bioavailability Study of Two Formulations of BCX7353

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Completed

An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Completed

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

Acute, Uncomplicated Human Influenza

United States, Australia, New Zealand, South Africa
BioCryst Pharmaceuticals

Completed

Study to Determine How BCX4161 is Metabolized and Eliminated by the Body

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Terminated

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Lymphoma | Leukemia

United States
BioCryst Pharmaceuticals

Completed

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

Leukemia, T-Cell

United States, Georgia
BioCryst Pharmaceuticals

Terminated

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) (RENEW)

Immunoglobulin A Nephropathy | Membranous Nephropathy | Complement 3 Glomerulopathy

France, Italy, Spain, United Kingdom
BioCryst Pharmaceuticals

Active, not recruiting

Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Hungary, France, Spain, Malaysia, South Africa, Korea, Republic of
BioCryst Pharmaceuticals

Completed

A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

Hereditary Angioedema | Prophylaxis | HAE

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Switzerland, United Kingdom, United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Serbia, Slovakia, South Africa, Spain
BioCryst Pharmaceuticals

Active, not recruiting

A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

United Kingdom, Austria, South Africa
BioCryst Pharmaceuticals

Terminated

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

Influenza

United States
BioCryst Pharmaceuticals

Terminated

Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema (OPuS-4)

Hereditary Angioedema | HAE

France, Belgium
BioCryst Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Influenza

United States, Canada
BioCryst Pharmaceuticals

Completed

Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE (OPuS-1)

Hereditary Angioedema

Germany, United Kingdom
BioCryst Pharmaceuticals

Completed

A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Completed

Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

Arthritis | Hyperuricemia | Gout | Joint Disease

United States
BioCryst Pharmaceuticals

Completed

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

Gout

United States
BioCryst Pharmaceuticals

Completed

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia

United States
BioCryst Pharmaceuticals

Completed

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

Lymphoma | Leukemia, Lymphocytic

United States
BioCryst Pharmaceuticals

Active, not recruiting

Berotralstat Treatment in Children With Hereditary Angioedema (APeX-P)

Hereditary Angioedema | Pediatric

Spain, Austria, Canada, France, Germany, Israel, Italy, Poland, Romania, United Kingdom
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
BioCryst Pharmaceuticals

Completed

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE (APeX-2)

Hereditary Angioedema | HAE

United States, Austria, Canada, Czechia, France, Germany, Hungary, North Macedonia, Romania, Spain, United Kingdom
BioCryst Pharmaceuticals

Completed

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Austria, South Africa
BioCryst Pharmaceuticals

Completed

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Romania, Switzerland, United Kingdom
BioCryst Pharmaceuticals

Completed

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Influenza

United States, South Africa
BioCryst Pharmaceuticals

Approved for marketing

Oral Berotralstat Expanded Access Program

Hereditary Angioedema | Prophylaxis | HAE
BioCryst Pharmaceuticals

Completed

A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions

Hereditary Angioedema

United Kingdom
BioCryst Pharmaceuticals

Completed

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks (OPuS-2)

Hereditary Angioedema | HAE

France, United Kingdom, Germany, United States, Belgium, Hungary, Italy, Canada
BioCryst Pharmaceuticals

Completed

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

Influenza

United States, Australia, Canada, Hong Kong, New Zealand, Singapore, South Africa
BioCryst Pharmaceuticals

Completed

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

Renal Insufficiency | Arthritis | Hyperuricemia | Gout | Joint Disease

United States
BioCryst Pharmaceuticals

Completed

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic

United States
BioCryst Pharmaceuticals

Completed

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia
BioCryst Pharmaceuticals

Completed

Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

Gout

United States
BioCryst Pharmaceuticals

Completed

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL),

United States, Australia, Germany, Italy, Spain, France, Austria, Finland, Switzerland, United Kingdom
BioCryst Pharmaceuticals

Withdrawn

Intramuscular Peramivir for the Treatment of Uncomplicated Influenza

Influenza
Midwestern University
Northwestern University; BioCryst Pharmaceuticals

Withdrawn

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

Renal Failure | Influenza

United States
BioCryst Pharmaceuticals

Completed

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Lymphoma

United States
BioCryst Pharmaceuticals

Completed

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Lymphoma

United States
BioCryst Pharmaceuticals

Completed

BCX-1777 in Treating Patients With Refractory Cancer

Cancer

United States
Chinese University of Hong Kong
BioCryst Pharmaceuticals

Completed

Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections

Influenza

China
BioCryst Pharmaceuticals
Department of Health and Human Services

Completed

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Fatigue | Myalgia | Cough | Headache | Nasal Congestion | Seasonal Influenza | Sore Throat

United States, Mexico, Canada, Australia, New Zealand, Puerto Rico
BioCryst Pharmaceuticals
Department of Health and Human Services

Terminated

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Cough | Fever | Headache | Nasal Congestion | Seasonal Influenza | Sore Throat

United States, Poland, Ukraine, Germany, Belgium, Argentina, Israel, Bulgaria, Serbia, South Africa, Brazil, Canada, Chile, Peru, Russian Federation, Hungary, Czech Republic, India, United Kingdom, Latvia, Bosnia and Herzegovina, ... and more
BioCryst Pharmaceuticals

Completed

A Study of Peldesine (BCX-34) in HIV-Infected Patients

HIV Infections

United States

Clinical Trials Sponsored by BioCryst Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations